Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Menkes Disease, Occipital Horn Syndrome, Unexplained Copper Deficiency
Interventions
Copper Histidine
Drug
Lead sponsor
Cyprium Therapeutics, Inc.
Industry
Eligibility
Up to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease

NCT07625605
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
Interventions
The MIND diet
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
30 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Elizabethton, Tennessee • Knoxville, Tennessee
Recruiting No phase listed Observational

Language in Primary Progressive Aphasia

NCT00537004
Conditions
Primary Progressive Aphasia
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease
Interventions
Terazosin therapy
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Friedreich Ataxia
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Novel PET Radioligand to Image OGA

NCT03632226
Conditions
Pharmacokinetics, Adult
Interventions
18F-OGA-1
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Conditions
Pantothenate Kinase-Associated Neurodegeneration
Interventions
Deferiprone oral solution
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
5 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Oakland, California
Conditions
Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration, Inflammation, Brain
Interventions
Lenalidomide 10 mg, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Completed Not applicable Interventional Results available

CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)

NCT04182763
Conditions
Pantothenate Kinase-Associated Neurodegeneration
Interventions
CoA-Z, Placebo
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Months to 89 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Completed Not applicable Interventional Accepts healthy volunteers

Alcohol and Immune Response

NCT03483389
Conditions
Alcohol Drinking, Alcohol; Harmful Use
Interventions
Alcohol, Ethyl, Alcohol, Ethyl - placebo
Drug · Other
Lead sponsor
Brown University
Other
Eligibility
21 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Conditions
Pantothenate Kinase-Associated Neurodegeneration
Interventions
Deferiprone oral solution, Placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
4 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Oakland, California
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Conditions
Alzheimer Disease
Interventions
MAR
Drug
Lead sponsor
Noah Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more
Conditions
Parkinson's Disease
Interventions
Gold Nanocrystals
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 2 Interventional Results available

Early Parkinson's Disease Monotherapy With CVN424

NCT06006247
Conditions
Parkinson's Disease
Interventions
CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance Beta, Inc.
Industry
Eligibility
30 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Conditions
Lewy Body Disease, Alzheimer Disease, Healthy
Interventions
Magnetic Resonance Imaging, Electroencephalography, Electromyography
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 95 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed No phase listed Observational Accepts healthy volunteers

Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)

NCT01838018
Conditions
Pantothenate Kinase-associated Neurodegeneration (PKAN)
Interventions
Not listed
Lead sponsor
Susan J. Hayflick
Other
Eligibility
7 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Obesity and Pediatric Multiple Sclerosis

NCT04593082
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 20 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Conditions
Childhood-Onset Neurodegeneration With Brain Atrophy (CONDBA)
Interventions
nL-UBTF-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed Not applicable Interventional Accepts healthy volunteers

Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach

NCT02614365
Conditions
Mild Cognitive Impairment
Interventions
Aerobic exercise, Stretch exercise
Behavioral
Lead sponsor
Howard University
Other
Eligibility
55 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, Healthy Aging
Interventions
AROMHA Brain Health Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts